Tim Hunt, JD
CEO
Alliance for Regenerative Medicine
Tim Hunt joined the Alliance for Regenerative Medicine (ARM) as CEO in 2022, bringing over 20 years of biotechnology leadership experience. A seasoned company builder with a focus on culture and strategy, he helps early-stage organizations foster cohesion and execute their missions. As CEO, Tim leads ARM’s global staff and serves as an advocate for its members and the broader cell and gene therapy sector.
Before joining ARM, Tim was Chief Culture and Corporate Affairs Officer at Xilio Therapeutics, where he advanced the company’s mission to develop tumor-selective immuno-oncology therapies. Previously, he served as Chief Corporate Affairs Officer at Editas Medicine, overseeing global policy, communications, bioethics, market development, and human resources. He has also held senior roles at Cubist Pharmaceuticals and Biogen.
Tim has contributed to several industry and policy groups, including the Duke-Margolis Center for Health Policy’s Value-Based Payments consortium, Life Science Cares’ Board of Directors, and the Ethics Committee of the American Society of Gene and Cell Therapy. He also served on ARM’s Gene Editing Task Force and BIO’s Gene Editing Working Group.
Tim holds a B.A. in history and philosophy from Boston College and a J.D. from Catholic University’s Columbus School of Law.
Sessions
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}